Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of atezolizumab versus docetaxel in previously treated advanced NSCLC
2013-003331-30Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Overall survival. Started Feb 2014; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-003331-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003331-30.